Spark licenses blindness gene therapy rights outside US to Novartis – Reuters
Endpoints News |
Spark licenses blindness gene therapy rights outside US to Novartis
Reuters In a statement, Spark said the deal leverages Novartis' “large, existing commercial and medical infrastructure in ophthalmology, as well as its commitment to commercializing genetic-based medicines.” Novartis, which sells opthalmology drugs including … Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal Novartis strikes $170m deal for ex-US rights to gene therapy for blindness Novartis Pays Spark $105M Up Front for Gene Therapy Rights Outside US |
